RE:RE:RE:RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025 If launching the distribution of its own drugs was so easy, big pharmas would not be that big as all biotechs would have done it. Which is obviously not the norm. That's why the jv route is the most productive one for biotechs. They avoid having to set up a sales team force, don't have to invest in costly marketing campaigns, don't have to pay competitive salaries to sales reps, etc .... They instantly have access to a well-established network of sales that already have its entries into uro-oncologists offices and that can generate much more faster revenues via royalties, on top of receiving upfront payments (that they wouldn't receive if they were going all alone).